Physicians' Academy for Cardiovascular Education
The potential incremental benefit of PCSK9 inhibition varies a lot among patients with stable CAD with the greatest benefit observed in younger patients with highest risk factor burden and high LCL-c levels.
In the EAGLES trial, smoking cessation pharmacotherapy did not increase the risk of serious CV disease or CV AEs in a general population of smokers without a history of CV disease.
Individuals with at least one laboratory-confirmed respiratory infection had a higher risk of MI or stroke, in particular when infected with S. pneumoniae or influenza virus.
A small study found antibodies in plasma and heart muscle of end-stage heart failure patients, and more so if HF was caused by ischemic heart disease than by cardiomyopathy.
In a retrospective survey of 133 patients with HoFH, the total serum cholesterol achieved by lipid-lowering therapies, was a major determinant of survival.
Different measures of fitness and physical activity were inversely associated with future CVD events and all-cause death, also in individuals with a high genetic CVD predisposition.
This conversation covers differences in efficacy and safety outcomes of treatment with DOACs or VKA, and how to decide what to give to whom and for how long, in light of the risk of antithrombotic and bleeding complications.
In this live webcast, recent clinical evidence on NOACs/DOACs in patients with both(AF and VTE were summarized.
ACC 2018 The MOMENTUM 3 study results show a large reduction in stroke and need for reoperation, as no pump thrombosis occurred, with the new Heartmate 3 device, in comparison with the Heartmate 2.
Levels of pro-inflammatory biomarkers were significantly elevated in decompensated compared with stable HF patients with preserved ejection fraction, and some were linked with altered diastolic function.
Patients with a history of MI who are closer to their most recent event, have had multiple prior MIs or have residual multi-vessel CAD, had higher CV risk reductions with evolocumab.
Ramadan starts on May 16. A study found that religious fasting is safe for patients with HFrEF, but non-adherence to medication and diet increases the risk of decompensated HF.
